Daiichi Sankyo Commits To Major Expansion In Germany As Part Of Global ADC Push

€1bn Investment

 
• By Lisa Takagi

Daiichi Sankyo will expand its production site in Pfaffenhofen, Germany with new R&D capability for antibody-drug conjugates, spending €1bn. Behind the major new investment, the firm has recently filed for the approval of two ADCs in the US and is preparing global approval filings including in Europe and Asia.

Expanding manufacturing capability ahead of its ADC candidates can be a key to stable supply.
Expanding ADC manufacturing capacity seen as key to stable supply • Source: Shutterstock

More from Anticancer

More from Therapy Areas